OBJECTIVE: The purpose of the economic evaluation of the German Drug-Eluting Stent (DES) registry includes the investigation of the economic impact and cost-effectiveness of DES compared to bare-metal stents (BMS) and between paclitaxel-eluting (PES) and sirolimus-eluting stents (SES). Here, methodology and initial results are presented. METHODS: Patients were recruited in 2005 and 2006 in 87 centres across Germany. Selection of PES, SES, or BMS was made at the discretion of the cardiologists in charge. Clinical, economic, and quality of life (QoL) data were collected at baseline and up to 12 months. Group comparisons were conducted using Fisher's exact and t test. RESULTS: Overall, 3,930 patients were enrolled: 3,471 (75% male, 65 ± 11 years) received DES and 458 (74% male, 67 ± 11 years) BMS. Among the DES patients, 1,821 received PES (75% male, 65 ± 10 years) and 1,600 SES (76% male, 65 ± 11 years). There were baseline differences in clinical and procedural characteristics but not in QoL. During the hospital stay, major adverse cardiac and cerebrovascular events occurred in 1.6% of DES (PES 1.9%, SES 1.1%) and 2.2% of BMS patients (BMS vs. DES, PES, and SES p = 0.327, 0.706, and 0.098, respectively). Hospital treatment costs were 4,989 ± 1,284 <euro> and 3,609 ± 924 <euro>, respectively, in DES and BMS patients (p < 0.001) with no significant difference between PES and SES. CONCLUSION: The economic evaluation of the large DES registry demonstrates increased initial hospitalisation costs associated with DES compared to BMS. Further analysis of the economic impact and cost-effectiveness of DES will provide estimates on large "real world" patient populations for decision makers and aid in reimbursement decisions of DES within the German and other health care systems.
OBJECTIVE: The purpose of the economic evaluation of the German Drug-Eluting Stent (DES) registry includes the investigation of the economic impact and cost-effectiveness of DES compared to bare-metal stents (BMS) and between paclitaxel-eluting (PES) and sirolimus-eluting stents (SES). Here, methodology and initial results are presented. METHODS:Patients were recruited in 2005 and 2006 in 87 centres across Germany. Selection of PES, SES, or BMS was made at the discretion of the cardiologists in charge. Clinical, economic, and quality of life (QoL) data were collected at baseline and up to 12 months. Group comparisons were conducted using Fisher's exact and t test. RESULTS: Overall, 3,930 patients were enrolled: 3,471 (75% male, 65 ± 11 years) received DES and 458 (74% male, 67 ± 11 years) BMS. Among the DES patients, 1,821 received PES (75% male, 65 ± 10 years) and 1,600 SES (76% male, 65 ± 11 years). There were baseline differences in clinical and procedural characteristics but not in QoL. During the hospital stay, major adverse cardiac and cerebrovascular events occurred in 1.6% of DES (PES 1.9%, SES 1.1%) and 2.2% of BMS patients (BMS vs. DES, PES, and SES p = 0.327, 0.706, and 0.098, respectively). Hospital treatment costs were 4,989 ± 1,284 <euro> and 3,609 ± 924 <euro>, respectively, in DES and BMS patients (p < 0.001) with no significant difference between PES and SES. CONCLUSION: The economic evaluation of the large DES registry demonstrates increased initial hospitalisation costs associated with DES compared to BMS. Further analysis of the economic impact and cost-effectiveness of DES will provide estimates on large "real world" patient populations for decision makers and aid in reimbursement decisions of DES within the German and other health care systems.
Authors: Gregg W Stone; Ali Rizvi; William Newman; Kourosh Mastali; John C Wang; Ronald Caputo; Julie Doostzadeh; Sherry Cao; Charles A Simonton; Krishnankutty Sudhir; Alexandra J Lansky; Donald E Cutlip; Dean J Kereiakes Journal: N Engl J Med Date: 2010-05-06 Impact factor: 91.245
Authors: E Regar; P W Serruys; C Bode; C Holubarsch; J L Guermonprez; W Wijns; A Bartorelli; C Constantini; M Degertekin; K Tanabe; C Disco; E Wuelfert; M C Morice Journal: Circulation Date: 2002-10-08 Impact factor: 29.690
Authors: Adnan Kastrati; Julinda Mehilli; Jürgen Pache; Christoph Kaiser; Marco Valgimigli; Henning Kelbaek; Maurizio Menichelli; Manel Sabaté; Maarten J Suttorp; Dietrich Baumgart; Melchior Seyfarth; Matthias E Pfisterer; Albert Schömig Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: David R Holmes; Martin B Leon; Jeffrey W Moses; Jeffrey J Popma; Donald Cutlip; Peter J Fitzgerald; Charles Brown; Tim Fischell; Shing Chiu Wong; Mark Midei; David Snead; Richard E Kuntz Journal: Circulation Date: 2004-02-10 Impact factor: 29.690